Using Ultrasound to Guide Fluid Treatment and Prevent Kidney Injury After Cardiac Surgery

What this Trial Is About

Researchers are investigating whether using ultrasound to evaluate venous congestion in the liver and kidneys can help guide treatment and prevent or manage acute kidney injury after cardiac surgery CSA-AKI. This trial focuses on patients developing CSA-AKI, a common and serious complication with significant risks including increased mortality and progression to chronic kidney failure. The study explores a new ultrasound method called the Venous Excess Ultrasound Score VEXUS to better assess venous congestion, which may improve individualized fluid and drug management compared to standard care. Participants are assigned to one of two groups a control group receiving standard care, and a treatment group where fluid and drug therapies are guided by VEXUS ultrasound measurements to minimize acute kidney injury. The trial involves daily monitoring of kidney function, fluid balance, and laboratory tests. The study uses randomized allocation without masking and collects data over the postoperative period up to ICU discharge. The VEXUS method combines ultrasound assessments of the inferior vena cava and Doppler evaluations of blood flow in liver and kidney veins. During the study, participants will have daily evaluations of kidney function including blood urea and creatinine levels at specific time points, alongside fluid balance tracking and laboratory examinations for up to seven days or until discharge. The researchers record all data for statistical analysis to determine if VEXUS-guided therapy improves kidney outcomes after cardiac surgery. The study includes monitoring for safety and effectiveness throughout the ICU stay and captures changes in renal function over time.

Prevention and Treatment of AKI VEXUS Guided Post Cardiac Surgery